Target intelligence / Profile preview

Lactate dehydrogenase B chain (LDH-B)

Target
LDH-B
Molecular classification
Enzyme
01

Overview

Lactate dehydrogenase B chain (LDH-B) is a protein subunit encoded by the LDHB gene. It assembles into tetramers (homotetramers or heterotetramers with LDH-A subunits) to form lactate dehydrogenase isoenzymes. LDH-B is most highly expressed in the heart and other aerobic tissues. The enzyme catalyzes the interconversion between pyruvate and lactate, coupled with NAD^+^/NADH cycling, playing a critical role in energy metabolism, especially during anaerobic glycolysis. It participates in metabolic adaptation, particularly in tissues needing rapid shifts between aerobic and anaerobic metabolism. Total LDH as well as specific isoforms (including LDH-B-rich forms) are used clinically as non-specific biomarkers for tissue injury and pathological conditions, particularly in cardiac and oncology contexts. Mutations in LDHB can cause a rare biochemical deficiency but do not typically produce clinical symptoms

Other names
L-lactate dehydrogenase B chainlactate dehydrogenase H chainLDH heart subunitLDH-BLDH-HLDHB_HUMANLDHBD
02

Mechanism of action

Enzyme inhibition (for research; inhibitors block the pyruvate–lactate conversion and alter cellular metabolism); Diagnostic biomarker usage (monitoring of tissue injury or disease)

03

Biological functions

Energy metabolismAnaerobic glycolysisInterconversion of pyruvate and lactateNADH/NAD^+^ turnover
04

Disease associations

Cardiovascular disease (as a tissue injury marker)Cancer (as a biomarker for tissue turnover or tumor burden)Other (lactate dehydrogenase deficiency, hereditary enzymopathies)
05

Safety considerations

Specific inhibition of LDH-B could theoretically impact cardiac energetics or induce metabolic disturbances in aerobic tissues, though these issues are largely theoretical in drug development at this time.Altered LDH-B activity is not typically associated with physical signs or symptoms, but dramatic disruption of lactate metabolism might be deleterious in theory
06

Interacting drugs

No small molecule drugs are widely used as direct LDH-B inhibitors or activators in clinical settings as of the latest reports; general LDH inhibitors (e.g., oxamate as a research tool) are non-selective among LDH isoforms.
07

Biomarkers

LDH-B levels (used as part of total LDH or isoenzyme assays) in serum or tissue can serve as markers of tissue injury, hemolysis, myocardial infarction, or certain cancers

Beyond the preview

Go deeper on Lactate dehydrogenase B chain (LDH-B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactate dehydrogenase B chain (LDH-B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call